TL;DR
Powers half the fancy skincare shelf. The injection is a different conversation entirely.
What is it? A tripeptide (glycine-histidine-lysine) bound to a single copper ion. ~200 ng/mL in young adults' plasma. Less than half that by age 60.
What does it do? Topically, delivers copper to collagen-crosslinking enzymes, firms skin, regrows hair follicles. In cell studies, shifts roughly 4,000 genes toward younger expression — the mechanism that drives interest in the injectable route.
Does the evidence hold up? Cleanly for topical. Placebo-controlled 12-week facial creams show measurable collagen and firmness gains. Injectable use rests on decades of animal work and zero randomized human trials.
Who uses it? Dermatology clinics, cosmetic formulators from drugstore to $300 serums, and off-label injectors chasing hair and scars.
Bottom line? Topical data is real. Injectable is mostly mechanism and vibes. Most people don't need the needle.
What It Is
GHK-Cu is the complex formed when the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys, or "GHK") binds a single copper(II) ion. It was first isolated from human plasma by Loren Pickart in 1973 at the University of California, San Francisco. Pickart spent the subsequent five decades characterizing its biological activity, and the bulk of the GHK-Cu literature traces back to his laboratory. His 2018 comprehensive review with Anna Margolina in the International Journal of Molecular Sciences (PMID 29986520) consolidates that half-century of work and is the most widely cited modern reference for the molecule.
GHK in its unbound form is a naturally occurring plasma peptide. Its serum concentration declines with age — from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 in the values most commonly cited by Pickart — a correlation used to frame GHK-Cu as a "youthful" signaling molecule whose decline tracks the age-related decline in connective-tissue repair capacity. Whether that correlation is causative or coincident remains an open question, but the framing is consistent across the literature.
What separates GHK-Cu mechanistically from most other peptides in the optimization space is the apparent scale of its gene-expression effect. Analyses using the Broad Institute's Connectivity Map (a database of genome-wide gene-expression responses to thousands of compounds) reported that GHK modulates the expression of roughly 4,000 human genes at a ≥50% expression-change threshold — a breadth not documented for any other peptide in common optimization use. Whether that breadth is therapeutically relevant, noise-inflated, or context-dependent is another open question, but it does help explain the diversity of effects reported in the preclinical literature.
GHK-Cu is by far the most-studied copper peptide and is the active compound in a large number of commercial cosmeceutical products. Topical use is the dominant legitimate route. Subcutaneous and intramuscular use for systemic effects — skin rejuvenation, hair growth, tissue repair — is widely practiced in the optimization community but is off-label and falls under the FDA's current Category 2 restriction for bulk injectable peptide substances.
Mechanism of Action
GHK-Cu is pleiotropic — it affects many biological pathways simultaneously. The mechanisms below are the best-characterized across Pickart's and independent groups' work.
- Copper delivery via carrier-exchange — The tripeptide binds Cu²⁺ with high affinity and delivers it to cells and tissues where it can be exchanged for use in copper-dependent enzymes. Lysyl oxidase (LOX, collagen cross-linking), superoxide dismutase 1 (SOD1, antioxidant), and tyrosinase all require copper as a cofactor. GHK-Cu's role as a physiological copper carrier is the mechanism most specifically attributable to the molecule.
- Collagen and elastin synthesis — GHK-Cu stimulates fibroblast collagen and elastin synthesis in vitro (Maquart et al. 1988, 1993). Part of the mechanism is copper-dependent activation of LOX, which cross-links collagen fibrils into durable matrix. Animal wound models consistently show accelerated collagen deposition and wound closure.
- Gene-expression modulation (Connectivity Map) — Pickart's CMap analyses identified modulation of ~4,000 human genes, with broad "reset" of gene-expression patterns in senescent fibroblasts toward younger baselines. Upregulation of DNA-repair, antioxidant, and extracellular-matrix genes; downregulation of pro-inflammatory and pro-fibrotic genes.
- Anti-inflammatory signaling — Downregulation of NF-κB, suppression of TNF-α and IL-6 production in stimulated fibroblasts and macrophages, and reduction of pro-inflammatory prostaglandin synthesis. Upstream compared with NSAID-style prostaglandin blockade.
- Anti-oxidant signaling — Upregulation of SOD1 and catalase activities; direct suppression of hydroxyl-radical formation via copper-chelation-mediated control of redox-active copper speciation. Paradoxically, the copper complex reduces copper-mediated oxidative damage by keeping Cu²⁺ in a less-redox-active form.
- Hair-follicle stem-cell activation — GHK-Cu enlarges hair follicles and prolongs the anagen (growth) phase in murine models (Pyo et al. 2007, Arch Pharm Res). Topical and intradermal applications have shown hair-growth benefits in small human studies.
- Skin barrier function — Topical GHK-Cu increases skin thickness, barrier lipid synthesis, and keratinocyte proliferation in cosmetic studies. Clinically meaningful improvements in fine lines, skin firmness, and photoaging markers are reported in multiple placebo-controlled cosmetic trials.
- Matrix metalloproteinase (MMP) regulation — GHK-Cu modulates MMPs and their tissue inhibitors (TIMPs), shifting the balance from matrix degradation toward matrix remodeling. Central to how it appears to improve scar quality and dermal firmness.
- Angiogenesis — Pro-angiogenic in wound-healing models (supports capillary sprouting and mature vessel formation), consistent with copper's role as cofactor for key angiogenic enzymes.
- Nervous-system / cognitive gene-expression analysis (Pickart 2017) — In-silico / in-vitro analysis suggests GHK modulates genes associated with nervous-system function and cognitive decline — hypothesis-generating rather than clinical.
- Cancer gene-expression modulation — In-vitro studies report downregulation of genes associated with metastatic breast (MCF-7) and prostate (PC-3) cancer cell lines; in-vivo oncology implications are not clinically settled.
What the Research Shows
GHK-Cu has one of the longest research histories of any compound in the peptide space. The literature spans foundational copper-chelation biochemistry, wound-healing models, cosmetic skin trials, and exploratory gene-expression analyses.
- Discovery and copper-carrier function (Pickart 1973; Pickart & Thaler 1973) — Original isolation from plasma, identification of copper-binding activity, and characterization of tripeptide structure.
- Copper-uptake mechanism (Pickart et al. 1980, Nature) — Demonstrated GHK facilitates cellular copper uptake.
- Collagen stimulation (Maquart et al. 1988, 1993) — Fibroblast collagen-synthesis stimulation in vitro and in vivo rat wound models.
- Wound healing in animals — Rat, rabbit, and pig studies demonstrating accelerated closure of incisional, excisional, diabetic, and chronic wounds with topical or injected GHK-Cu.
- Chronic leg ulcers (human; early 1990s, Pickart / ProCyte) — Clinical work demonstrating improved healing of venous stasis ulcers and pressure ulcers with topical GHK-Cu formulations.
- Cosmetic skin trials (Abdulghani 1998; Leyden 2002 and subsequent) — Placebo-controlled clinical studies of topical GHK-Cu cream in photoaged skin reporting improvements in collagen density, skin thickness, fine-line reduction, and firmness over 12 weeks.
- Hair growth (Trachy 1999; Pyo 2007) — Animal and small human studies showing accelerated hair-follicle enlargement, prolonged anagen phase, and increased hair density with topical and intradermal GHK-Cu.
- Skin regeneration review (Pickart, Vasquez-Soltero & Margolina 2015, Biomed Res Int) — Summarized in-vivo and in-vitro evidence for skin regeneration across species.
- Emphysema gene-expression signal (Campbell 2012, PMID 22937864) — Independent group reported that GHK reverses a gene-expression signature associated with emphysema-related lung destruction in ex-vivo lung tissue — a non-skin application of the gene-expression framework.
- CNS gene-expression (Pickart 2017, Brain Sci) — In-silico analysis of GHK effects on genes relevant to cognitive decline. Hypothesis-generating rather than clinical.
- Regenerative and Protective Actions (Pickart & Margolina 2018, PMID 29986520) — Comprehensive 50-year synthesis review. The most-cited modern GHK-Cu reference.
- Topical penetration data (Hostynek 2011, PMID 20835751) — Characterized penetration of the copper tripeptide across skin layers in vitro.
- Modern cosmeceutical validation — GHK-Cu is an active ingredient in many clinically tested cosmetic products. Independent placebo-controlled trials report modest but consistent cosmetic-grade improvements.
Honest Evidence Framing
Topical GHK-Cu has the best-supported use case — placebo-controlled trials of cosmeceutical formulations show measurable improvements in skin collagen, firmness, and fine lines. Systemic SubQ use is supported by mechanism and animal data, not by human RCTs. A large fraction of the supportive literature traces back to a single laboratory (Pickart's), analogous to BPC-157's concentration in Sikiric's group, and similar independent-replication cautions apply.
Human Data
Human evidence for GHK-Cu is concentrated in topical cosmetic and chronic-wound applications; systemic injectable human evidence is extrapolation.
- Venous leg ulcers (ProCyte, 1990s) — Topical copper-peptide formulations tested in chronic wound care with positive healing outcomes in controlled clinical settings.
- Photoaged skin cosmetic creams (Abdulghani 1998; Leyden 2002; subsequent) — Multiple 12-week placebo-controlled trials of GHK-Cu-containing cosmetic creams reporting collagen density, skin thickness, firmness, and fine-line improvements.
- Diabetic ulcers — Small clinical series with topical GHK-Cu reporting accelerated closure; underpowered for formal conclusions.
- Hair growth — Small clinical studies on topical / intradermal GHK-Cu reporting increased hair density and terminal-hair conversion; practice continues to explore.
- Post-procedural skin — Dermatology case series exploring GHK-Cu in post-laser, post-microneedling, and post-surgical skin recovery.
- Cosmetic market penetration — Hundreds of commercial GHK-Cu products have been sold since the 1990s, generating post-market exposure data with a clean safety record at topical doses.
- No systemic RCT — No randomized controlled trial of systemic SubQ or IM GHK-Cu for anti-aging, tissue-repair, or cognitive endpoints has been published in a peer-reviewed journal.
This is a compound whose topical human data is real and clinically positive, and whose systemic injectable data is still largely preclinical / mechanistic with meaningful safety extrapolation from topical use. Off-label SubQ use carries the usual gray-market considerations — compound purity, appropriate dose, sterile technique.
Dosing from the Literature
The following synthesizes cosmetic-product concentrations, practitioner protocols, and the preclinical literature.
| Route | Concentration / Dose | Frequency | Notes |
|---|
| Topical (cosmetic serum) | 0.05–2% | 1–2x daily | Most clinical cosmetic trial formulations use 0.1–2%. Apply to clean skin; avoid mixing with vitamin C in the same application. |
| Topical (professional / intensive) | 2–5% | Post-procedure or daily | Higher-concentration products used after microneedling, laser, or as intensive anti-aging applications. |
| Subcutaneous (community) | 1–3 mg | Daily or 5x per week | Most commonly reported SubQ dose. Rotate injection sites. Short half-life suggests distributed timing. |
| Intradermal / mesotherapy | Microinjections, low volume | Monthly to weekly | Used by dermatology practitioners for localized skin-quality applications. |
| Cycle length | 8–12 weeks | — | Followed by 4 weeks off. Topical application is often continuous in cosmetic context. |
Dosing Disclaimer
GHK-Cu topical dosing is extensively validated in cosmetic trials. SubQ and intradermal dosing are off-label community practice without a controlled human trial validating the dose range. Avoid high chronic injected doses; the copper load from sustained SubQ GHK-Cu has not been formally characterized for systemic copper overload risk.
Reconstitution & Storage
Injectable GHK-Cu is typically supplied as a lyophilized blue-colored powder (the copper complex imparts the color) in 50 mg, 100 mg, or 200 mg vials.
| Vial Size | BAC Water | Concentration | 1 mg Dose | 2 mg Dose |
|---|
| 50 mg | 2 mL | 25 mg/mL | 4 units (0.04 mL) | 8 units (0.08 mL) |
| 100 mg | 4 mL | 25 mg/mL | 4 units (0.04 mL) | 8 units (0.08 mL) |
| 100 mg | 2 mL | 50 mg/mL | 2 units (0.02 mL) | 4 units (0.04 mL) |
| 200 mg | 4 mL | 50 mg/mL | 2 units (0.02 mL) | 4 units (0.04 mL) |
- Reconstitution — Inject bacteriostatic water slowly down the vial wall at 45°; swirl gently. Reconstituted solution is clear blue (copper signature). Do not shake.
- Storage — Unreconstituted: 2–8°C preferred, room-temp tolerable short-term. Reconstituted: refrigerated 2–8°C, use within 28 days. Do not freeze reconstituted peptide.
- Topical formulations — Water-based serums with 0.05–2% GHK-Cu; avoid formulations with high ascorbic acid because it can reduce Cu²⁺ to Cu¹⁺ and destabilize the complex. Applying vitamin C in the morning and GHK-Cu in the evening is standard practice.
- Injection sites — SubQ into abdomen (2" from navel), thigh, or upper arm. Rotate sites.
- Inspection — Solution should remain a clear blue color. Discard if cloudy, colorless, greenish, or particulate.
→ Use the Kalios Peptide Calculator for exact syringe units
Side Effects & Risks
Important
Topical GHK-Cu has decades of clean cosmetic-market data. Injectable data is thinner, and copper overload remains the uncharacterized risk. Bring this to your provider before going injectable.
Topical GHK-Cu has one of the cleanest safety profiles of any bioactive peptide due to decades of cosmetic-product use. Injectable use has less human-data safety depth but no major red flags in the published record.
- Topical irritation (rare) — Mild erythema or itch at the application site in sensitive skin. Resolves with dose reduction or vehicle switch.
- Injection-site reactions — Transient local redness, tenderness, occasional bruising. Self-limited within 24 hours.
- Blue-green staining — The copper complex can leave a temporary blue-green tint on cotton, clothing, or bedding if topical product transfers. Cosmetic only, not a medical concern.
- Copper overload (theoretical) — Chronic high-dose systemic injection of copper-containing peptides has never been rigorously characterized. Ceruloplasmin capacity is large, but prolonged daily injection of mg-range GHK-Cu is an uncharacterized load. In practice, total copper delivery from typical published doses remains well within conservative safety margins.
- Iron / zinc competition — Chronic copper elevation can perturb zinc and iron balance. Routine CBC and ferritin tracking is reasonable for long-term users.
- Interactions with high-dose vitamin C — Ascorbate reduces Cu²⁺ to Cu¹⁺ and destabilizes the GHK-Cu complex. Separating application / dose timing is standard practice.
- Pre-existing cancer — Pro-angiogenic mechanisms warrant caution with active malignancy. In-vitro data suggest anti-metastatic gene modulation in some cancer lines, but in-vivo tumor-bearing host data are insufficient for a clean recommendation.
- Wilson's disease / copper-overload conditions — Contraindicated.
- Pregnancy / lactation — Not studied; avoid.
- Purity concerns — The blue color is an inherent property of the Cu²⁺ complex; cream-white "GHK-Cu" powder suggests degraded copper content or improper labeling. Third-party HPLC + metal analysis is the floor for quality sourcing.
- WADA status — Not specifically named on the Prohibited List as of 2026; no major performance-enhancing profile documented. The tissue-repair peptide class could plausibly be evaluated under S0 for tested athletes. Consult federation guidance.
Bloodwork & Monitoring
Monitoring for GHK-Cu is minimal for topical use. Systemic injection users may consider periodic copper-related labs.
- Baseline CMP and CBC — Standard baseline; repeat at 8–12 weeks for long-duration injection protocols.
- Serum copper + ceruloplasmin — For extended injectable use (>3 months), reasonable to document baseline and recheck.
- Serum zinc + ferritin — Baseline; recheck with long-duration use to track copper-zinc-iron balance shifts.
- 24-hour urinary copper — If clinical concern for copper overload arises.
- Skin photography / tracking — For cosmetic applications, standardized before / after photographs are the most reliable outcome measure.
- Hair density / scalp photography — If hair growth is a target endpoint.
- Cancer screening (age-appropriate) — Given the pro-angiogenic mechanism, reasonable before chronic systemic use.
Commonly Stacked With
Different mechanism — BPC-157 drives local angiogenesis and growth-factor upregulation; GHK-Cu modulates gene expression and connective-tissue matrix. Commonly combined for skin and tissue-repair protocols. Core of the GLOW Stack (GHK-Cu + BPC-157 + TB-500).
Systemic actin-mediated tissue repair plus cell migration. Complements GHK-Cu's matrix-focused mechanism. Standard pairing in advanced recovery protocols.
Tetrapeptide telomerase-modulating / pineal peptide. Paired with GHK-Cu in longevity protocols — two peptides with broad gene-expression effects but different target systems. Evidence for combined benefit is practitioner-level.
Retinoids (topical)
Tretinoin or retinaldehyde is the most evidence-rich anti-aging skin agent. Topical GHK-Cu at night plus retinoid on alternate nights is a common layered cosmetic protocol. Copper-complex stability in high-strength retinoid formulations requires formulation expertise — which is why copper-free GHK is sometimes formulated with retinoids instead.
Vitamin C (topical, morning)
Potent antioxidant and collagen cofactor. Timing-separated from GHK-Cu (AM vs PM) to avoid copper-redox destabilization by ascorbate.
→ Check compound compatibility in the Stack Builder
Practical User Notes
Read This First
Topical GHK-Cu is widely and legitimately available as a cosmetic ingredient. Injectable GHK-Cu is off-label and falls under FDA Category 2 restriction. The notes below reflect aggregated community and practitioner practice. They are informational, not medical guidance.
- Topical first — For cosmetic / skin-quality / hair applications, start with topical. It has the best evidence, lowest risk, and fewest logistical burdens. Most users will get the benefit they are seeking without needles.
- Look for the blue color — Authentic GHK-Cu (topical or injectable) carries a blue signature from the Cu²⁺ complex. A "GHK-Cu" cream that is white or an injectable powder that is off-white is suspect.
- Time-separate from vitamin C — Vitamin C serum AM; GHK-Cu serum PM. Mixing in the same application destabilizes the copper complex via ascorbate-driven Cu²⁺ reduction.
- SPF every day — UV degrades the dermal matrix faster than any peptide can build it. Broad-spectrum sunscreen is a non-negotiable adjunct for any anti-aging skin protocol.
- Layering with retinoid — Tretinoin + GHK-Cu alternate-night protocols are common in dermatology. Avoid combining in the same application (irritation + copper-complex instability). The copper-free GHK form is a better same-formulation partner for retinoids than GHK-Cu.
- SubQ injection technique — 29G–31G half-inch insulin syringe; SubQ at 45°; abdomen or thigh; rotate sites.
- Dose spacing — Short plasma half-life suggests distributed daily dosing over chunked weekly dosing for systemic applications, though no clinical trial has compared.
- Cycle structure — 8–12 weeks on / 4 weeks off is the common injected-use cycle. Topical can be continuous.
- Post-procedure use — After microneedling, peels, or laser: topical GHK-Cu at higher concentration (2–5%) applied starting ~48 hours post-procedure (once wound-healing phase permits), then daily.
- Sourcing discipline — Topical cosmeceuticals: buy from established brands with clinical documentation. Injectable: third-party HPLC + metal analysis COAs are the floor.
- Expectations calibration — 12-week cosmetic trials show real but modest improvements (10–25% on objective skin measures). Dramatic visual transformations in 2–4 weeks are unrealistic and usually marketing-driven.
- Red flags to stop — Persistent skin irritation at topical dose, injection-site reactions that do not resolve, unexplained systemic symptoms on long-term injected use, or new laboratory abnormalities on routine bloodwork.
Regulatory Status
Current Status — April 2026
Topical GHK-Cu is a widely used cosmetic ingredient in the United States and European Union (INCI: "Copper tripeptide-1"). It is not regulated as a drug in cosmetic applications and has decades of post-market safety data.
Injectable GHK-Cu is classified by the FDA as a Category 2 Bulk Drug Substance, making it ineligible for compounding pharmacy use under sections 503A / 503B. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced an intention to reclassify approximately 14 of the 19 Category 2 peptides back to Category 1. Public statements have indicated GHK-Cu is among those slated for reclassification, but as of April 2026 the FDA has not issued a formal update and the Pharmacy Compounding Advisory Committee (PCAC) has not completed review. Compounding remains prohibited.
GHK-Cu is not specifically named on the WADA Prohibited List and has no major performance-enhancing profile. The tissue-repair peptide class could plausibly be evaluated under S0 (non-approved substances) for tested athletes.
Community injectable GHK-Cu is sourced through gray-market research-chemical vendors. Topical cosmetic use remains the legitimate and widely available pathway.
Cost & Access
GHK-Cu is available in two distinct channels:
Topical cosmetic (legitimate OTC): GHK-Cu is widely used as a cosmetic ingredient at concentrations of 0.1–2% in consumer serums and creams (Skin Biology, NIOD, The Ordinary, and many others). Topical use does not require prescription.
Research-only injectable: U.S. compounding pharmacies cannot legally compound GHK-Cu for parenteral use under current FDA bulk-substance rules (Category 2 designation). Injectable GHK-Cu is available only through research-chemical suppliers for laboratory research purposes. Kalios does not sell compounds.
GHK-Cu is among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 Category 2 reclassification announcement. If reclassified back to Category 1 (subject to Pharmacy Compounding Advisory Committee review and FDA implementation), 503A compounded GHK-Cu would become available to clinician-prescribed patients under compounding-pharmacy rules. As of April 2026, this reclassification remains pending and GHK-Cu cannot be legally compounded for parenteral administration by 503A or 503B pharmacies in the United States.
Access and regulatory status as of April 2026. Actual availability varies by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching GHK-Cu often also look at these:
Three-way head-to-head of the top tissue-repair peptides. Mechanism, evidence, dosing, and why the three are stacked together in Wolverine and GLOW.
KPV + GHK-Cu + BPC-157 + TB-500 — anti-inflammatory and tissue-repair protocol emphasizing gut and immune modulation.
GHK tripeptide without the copper ion. Retains partial gene-modulating activity but weaker tissue-repair signaling.
Fragment of the GHK-Cu molecule studied for its role in gene expression and copper delivery.
Alanine-Histidine-Lysine copper peptide. Used primarily in hair-follicle activation and topical scalp formulations.
Palmitoyl-GHK (palmitoyl tripeptide-1). Lipophilic cosmetic version of GHK for topical anti-aging formulations.
Key References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4351857. (Original discovery publication.)
- Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. PMID: 7432330.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
- Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. doi:10.3390/ijms19071987. (Comprehensive modern review.)
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730.
- Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278.
- Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev. 2012;2012:324832. PMID: 22666521.
- Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17702486.
- Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864.
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20835751.
- Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171.
- Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306. PMID: 19129717.
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012;69(6):1303-1306. PMID: 23285693.
- Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012;18(11):685-690. doi:10.1002/psc.2455. (Copper-independent activity comparator.)
- Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. Thermodynamic study of Cu²⁺ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID: 21748269.
- Mazurowska L, Mojski M. Biological activities of selected peptides: skin penetration ability of copper complexes with peptides. J Cosmet Sci. 2008;59(1):59-69. PMID: 18350230.
- Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of healing of cutaneous wounds in mice. Arch Int Pharmacodyn Ther. 1995;330(3):345-360. PMID: 9060874.
- FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026.
- WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org.
Last updated: April 2026 | Profile authored by Kalios Peptides research team